Impact of an e-Bug Educational Intervention on HPV Vaccine Uptake in Middle School Students
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCentre Hospitalier Universitaire de Nice
About this trial
This study is a non-interventional observational pilot analysis assessing the possible impact of an educational programme (e-Bug) on parental consent and HPV vaccination uptake during the 2023-2024 and 2024-2025 national school-based HPV vaccination campaigns in France. The study focuses on one middle school in the Alpes-Maritimes department where teachers and the school nurse had been previously trained on HPV and used e-Bug educational resources in class as part of routine health education. No research-related intervention was conducted, and the educational programme was not introduced or modified for the purpose of the study. Only aggregated and anonymised vaccination data were used. These data were routinely collected by the Regional Health Agency (ARS PACA) as part of the national vaccination programme and transmitted for analysis. Aggregated data from the pilot school were compared with departmental-level outcomes to describe whether an upstream educational approach may be associated with improved parental acceptance and higher HPV vaccination coverage. This study aims to contribute to the understanding of educational determinants of vaccine uptake in a real-life school setting without involving any participant recruitment or individual data collection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
No individual participants are enrolled. The study uses only aggregated, anonymised vaccination data routinely collected by ARS PACA
Disqualifiers
Not applicable. No individual-level inclusion or exclusion criteria are defined, as no participants are enrolled.
Trial population
Aggregated data from 5th-grade students enrolled in one pilot middle school using the e-Bug programme, compared with aggregated data from all other middle schools in the Alpes-Maritimes department. No individual-level data were accessed.
Trial design
Design model
Ecologic or community
Time perspective
Retrospective
Treatments tested in this trial
Consent for HPV vaccination
Other interventionConsent for HPV vaccination
Treatment groups
11,000 Participants
are divided into 2 treatment groupsGroup A: Pilot School Using e-Bug Programme1 intervention
Group B: Other Middle Schools in Alpes-Maritimes Department1 intervention
Trial outcomes
Primary outcomes
1
HPV vaccination uptake (1st and 2nd doses) in the pilot school compared with departmental data
e-Bug educational programme
Time frame
From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)Secondary outcomes
1
Parental consent rate (acceptability)
Aggregated proportion of parents providing positive consent for HPV vaccination in the pilot school, compared with aggregated departmental consent rates collected by ARS PACA during the 2023-2024 and 2024-2025 school-based campaigns.
Time frame
From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)2
Response rate (return of vaccination authorisation forms)
Aggregated rate of returned parental authorisation forms (regardless of response: yes/no) in the pilot school compared with departmental response rates.
Time frame
From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov